TORONTO, Jan 21, 2026, 17:13 EST
Manulife Financial Corp announced it will report its fourth-quarter and full-year 2025 earnings after the market closes on Feb. 11. A webcast and conference call are scheduled for Feb. 12 at 8 a.m. Eastern time. The Toronto-based insurer and wealth manager operates under the Manulife name in Canada, Asia, and Europe, and as John Hancock in the U.S. It trades under the ticker MFC on the Toronto, New York, and Philippine stock exchanges, and as 945 in Hong Kong. 1
The scheduling note arrives just as some analysts reevaluate their price targets, anticipating a results update that could shift sentiment fast. According to a Yahoo Finance commentary, several have revised their estimates for Manulife’s shares while reexamining the company’s outlook. 2
Kalkine Media highlighted Manulife in its TSX 60 report, noting “mixed moves” with a short-term decline occurring alongside stronger medium-term momentum. 3
Simply Wall St reported that Manulife shares dropped 2.9% in one day and fell 0.9% over the past week, though they posted stronger gains over three months and the past year. The stock’s last close stood at CA$50.63. It trades at a price-to-earnings ratio of 15.7, above the North American insurance sector average of 12.8, according to the outlet. The report cited Sun Life Financial and E-L Financial as comparable Canadian peers. 4
On Feb. 11, investors will get an updated look at how the year wrapped up for a company blending traditional insurance with wealth and asset management.
StockTitan’s announcement noted the company will archive the webcast on its investor site, with the replay of the call accessible through May 12. The notice included dial-in information for the conference call. 5
That calendar date works both ways. If February’s numbers or outlook miss the mark against shifting targets and valuation expectations, the stock can react sharply.
Life insurers’ earnings often fluctuate alongside markets and interest rates, impacting both their investment income and the valuation of long-term liabilities.
Manulife has made its move by setting the clock. The debate over its value will have to wait for the results—and for management’s next statement.
